Gentzler, Ryan D
University of Virginia Cancer Center
3 papers on CoChatORCID 0000-0002-8983-6677
Most cited papers
- Verified
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 1,404
- Verified
A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F. (2017) · Cancer Immunology, Immunotherapy
Cancer Immunotherapy and BiomarkersDiabetes and associated disorders
Cited by 121
- Verified
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
Neal, J. W., Santoro, A., Viteri, S., Ponce Aix, S., Fang, B., Lim, F. L., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., et al. (2022) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free